Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Dermegen
Auburn, Alabama, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Dermegen was a biotechnology company focused on the development of synthetic lytic peptides for treating infectious diseases and promoting wound healing. The company's proprietary technology platform produced peptides designed to selectively destroy pathogens by disrupting their cell membranes without harming human cells. Its lead product candidate, D2A21 (demegel), was developed as a topical agent for burn wounds and skin infections. Dermegen's assets and intellectual property were acquired by Healthpoint in 2005 to bolster their dermatology and wound care portfolio.
- Therapeutic areas
- DermatologyInfectious Diseases
- Modalities
- Peptides
- Industry
- Biotech
02
Partnerships
Healthpoint
Beyond the preview
Go deeper on Dermegen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dermegen.